Join our Community
Support ToI and remove all ads
Learn more
×

patent filings

This satellite image released by the European Space Agency shows oil leaking from a grounded UK-sanctioned tanker near Qibliyah Island off the coast of Oman, July 28, 2026. (European Space Agency via AP)
Israeli scientists develop huge sponge to mop up and ‘eat’ oil spills
By Sue Surkes
Ben-Gurion University scientists say plant material, enriched with nutrients to attract oil-guzzling bacteria, can absorb 100 times its own mass in crude oil or fuel in just seconds
In this photo illustration, a woman holds a fidget spinner, May 5, 2017 in the Brooklyn borough of New York City. (Drew Angerer/Getty Images/AFP)
May 12, 2017, 3:12 pm
Was media spun in fidget toy’s invention tale?
Investigation shows that Catherine Hettinger’s original device has little in common with popular spinner sold today
By JTA
Mellanox headquarters in Yokne'am (Moshe Shai/Flash90)
February 2, 2015, 6:24 pm
Israel 5th in Bloomberg tech ranking, ahead of US, UK
The country needs a billion-dollar ‘tech unicorn’ to break through to the top, say experts
By David Shamah
Illustrative photo of a vaccination. (Miriam Alster/Flash90)
October 29, 2014, 3:33 pm
Israel’s universal flu vaccine heads for universal acceptance
With new patent approvals, BiondVax is ready to license its unique influenza treatment to pharma firms and governments
By David Shamah
From the WebSeptember 3, 2014, 5:05 pm
UK court backs Teva rival to AstraZeneca lung drug
Reuters: The Israeli drug company has a clear path to continue with the introduction of its new inhaler in the UK
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
From the WebJuly 3, 2014, 7:11 pm
Teva files petition with U.S. FDA against MS drug competitors
Reuters: In its latest bid to stave off Copaxone competition, the Israeli company filed a ‘citizen’s petition’
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
From the WebApril 20, 2014, 1:36 pm
Teva rejected on generic Copaxone delay
Businessweek: The Israeli pharma giant cannot stop competitors from producing their own versions of the drug, even as it seeks to extend its patent
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
From the WebApril 1, 2014, 11:57 am
A fight over generic drugs heads to high court
Wall Street Journal: The top legal body in the US is willing to let Teva argue that Copaxone’s patent should be revived
From the WebMarch 11, 2014, 1:59 pm
Teva’s Copaxone conversion effort persuading analysts
Businessweek: A campaign to ‘convert’ users to a new version of the drug — with a long patent life — seems to be paying off
From the WebJune 19, 2013, 5:09 am
Teva to stop filing for patents in Israel
Globes: Pharmaceutical giant prefers to file in Switzerland where it can enjoy substantial tax breaks
Students participate a mass chemistry experiment in Tel Aviv University last September, a re-enactment of an experiment performed in the space shuttle Columbia in 2003 by the first Israeli astronaut in space – the late Colonel Ilan Ramon. The re-enactment, one of 13 conducted at Israeli institutions, was part of an attempt to break the Guinness World Record for "largest chemistry lesson at multiple venues.” Guinness presented the award to the participating institutions last November (photo credit: Gili Yaari/Flash90)
March 19, 2012, 6:21 am
Israeli universities net top honors in global rankings
Two key indices of academic achievement place Israeli institutions of higher learning among the world’s most important
By David Shamah
Load More

Sign in or Join The Times of Israel Community

Sign in or Register

Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Sign in or Register
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.